The US Food and Drug Administration’s efforts to build a framework for speeding responses to emerging infectious diseases and biowarfare threats – collectively known as medical countermeasures – have seen far more use by diagnostics developers than by drug and vaccine sponsors, but the agency’s multi-pronged MCM initiative is readying potential responses to the emerging coronavirus.
“FDA stands ready to work with medical product developers to clarify regulatory and data requirements necessary to move products forward...
